Stock Earnings

Question 1

Spyre Therapeutics Inc'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, Spyre Therapeutics Inc'in toplam varlıkları $608 olup, net loss $-208'dir.

Question 2

SYRE'ün temel finansal oranları nelerdir?

Accepted Answer

Spyre Therapeutics Inc'in cari oranı 6.75, net kâr marjı 0, hisse başına satış $0'dir.

Question 3

Spyre Therapeutics Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

Spyre Therapeutics Inc largest revenue segment is Biopharmaceutical Products, at a revenue of 886,000 in the most earnings release.For geography, United States is the primary market for Spyre Therapeutics Inc, at a revenue of 886,000.

Question 4

Spyre Therapeutics Inc kârlı mı?

Accepted Answer

no, son mali tablolara göre Spyre Therapeutics Inc'in net loss $-208'dir.

Question 5

Spyre Therapeutics Inc'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, Spyre Therapeutics Inc'in yükümlülüğü 90'dir.

Question 6

Spyre Therapeutics Inc'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

Spyre Therapeutics Inc'in toplam tedavüldeki hisse sayısı 60.25'dir.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	--	0	0	2	18	0
Revenue Growth (YoY)	--	--	-100%	-89%	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	--	45	34	28	27	21
Research & Development	--	162	84	58	57	59
Operating Expenses	--	208	118	87	84	81
Other Non Operating Income (Expenses)	--	-20	-121	0	0	0
Pretax Income	--	-207	-338	-83	-65	-80
Income Tax Expense	--	0	0	0	0	--
Net Income	--	-208	-338	-83	-65	-80
Net Income Growth	--	-38%	307%	28%	-19%	3%
Shares Outstanding (Diluted)	--	47.02	6.89	3.37	2.63	2.13
Shares Change (YoY)	--	582%	105%	28%	23%	66%
EPS (Diluted)	--	-4.42	-49.12	-24.86	-25.02	-37.97
EPS Growth	--	-91%	98%	-1%	-34%	-38%
Free Cash Flow	-154	-157	-99	-80	-54	-80
Free Cash Flow Per Share	--	-3.33	-14.35	-23.73	-20.53	-37.55
Gross Margin	--	--	--	--	--	--
Operating Margin	--	0%	0%	-4,200%	-361.11%	0%
Profit Margin	--	0%	0%	-4,150%	-361.11%	0%
Free Cash Flow Margin	--	0%	0%	-4,000%	-300%	0%
EBITDA	--	-208	-117	-83	-64	-80
EBITDA Margin	--	0%	0%	-4,150%	-355.55%	0%
D&A For EBITDA	--	0	0	1	1	1
EBIT	--	-208	-117	-84	-65	-81
EBIT Margin	--	0%	0%	-4,200%	-361.11%	0%
Effective Tax Rate	--	0%	0%	0%	0%	--

Spyre Therapeutics Inc (SYRE) Price

SYRE Stock Price Chart

SYRE Income

Follow-Up Questions